2020 The Year Of RAP, page-964

While listening to the videoed Morgans presentation of last week by TK I recorded the few notes below. Several of the points made I think add clarity to earlier HC discussions. The nature and projected use of the consumer health product is interesting.

Sorted notes are below, with no responsibility taken for any misinterpretations.

Video link:


General
We have good patent protection with additional applications under assessment.

Coviu is RAP’s first commercial deal. It involves integrating our software into their platform.

For individual use all processing is done on the phone itself with no involvement of Cloud storage.

We have over 6,000 recorded cough sounds in our database confirmed by clinical analyses.

Five areas are targeted for commercialisation.

Across all platforms a common price will be charged: $5 to $10 per use.

An Industry Advisory Board has been established in the US with a highly qualified and experienced membership.

A subsidiary has just been set up in the UK to sell point-of-care diagnostics.

Telehealth
ResApp-Dx will not be sold as a separate app but will be embodied in each telehealth provider’s application software.

Telehealth clinicians are concerned about the liability associated with diagnosis at a distance and are expected to welcome the availability of the app to support their clinical opinions.

Hospital emergency departments (EDs) – the app will be used for fast triage purposes.

Time is a very important KPI factor in hospitals, particularly in EDs, and the app fits well with this.

Hospital uptake for diagnostic use will be slower than for telehealth but in time it may be a larger market in the end.

Our discussions focus has been on hospitals already using smart phones for other digital health purposes.

We are developing our own hardware for use in hospitals.

Hospitals prefer not to use phones for several reasons, including the possibility of them being stolen. They have several options for phones or hardware use. Our handheld hardware probably will be given to them essentially for free.

Our initial commercial focus is on ED triage use. We will ill not be replacing existing tests such as X-rays.

Direct to Consumer
This market initially was given low priority. This has changed with the involvement of Sanofi.

Expected that the Sanofi product will be used to allow a consumer to decide whether to go to a chemist, to a GP, to a hospital ED or to use telehealth.

Work with Sanofi is ongoing and has a March milestone. This project is “really exciting”.

Was in Germany last week. Very excited about what is going on there and about the next stages.

We will develop the software product for Sanofi and they will use it to develop and sell a consumer product and pay us according to use.

We have been developing a minimal product, which Sanofi will test in ‘consumer land’ and based on results we will move on from there.

Chronic Disease Management
A separate product that is intended for daily disease monitoring and management.

Unlike normal chronic disease management we have the advantage of no extra device being required. Normally a patient is given a device that they leave in the bottom drawer. A phone is always in a pocket and accessible.

We also have the unique ability to monitor severity, thereby providing a guide to changes in required medication according to the level of severity indicated.

Home Screening for OSA
A major reason why 80% of OSA is not diagnosed is the complicated, uncomfortable and costly procedure currently required. This could be overcome by simple use of a phone on the bedside table overnight.

The OSA app measures breathing patterns as well as snoring sounds.

The levels of accuracy in our OSA clinical results are similar to the current complex diagnostic method.

Expectations for the next six months
(1) Key regulatory decisions from the FDA and the TGA, with the TGA likely sooner.
(2) Expecting Sanofi to take up its option in March and to go forward.
(3) Great opportunities for commercial deals in telehealth. We are working with Coviu already, and expect to mirror that involvement with other telehealth providers in Europe and the US.
(4) We expect OSA regulatory progress and a product to be on the market later this year.
(5) Availability of prototype wearables and handheld devices is expected shortly.
(6) We are working with a German hospital network and are in discussions with a number of other hospitals as well. Because we are not replacing any current product such as chest X-rays it should be much easier to enter the hospital market.
(7) We expect to be announcing a number of commercial deals over the next six months.